NASDAQ: PEPG - PepGen Inc.

Yield per half year: -23.39%
Sector: Healthcare

Share chart PepGen Inc.


About

PepGen Inc., биотехнологическая компания клинической стадии, занимается разработкой олигонуклеотидных терапевтических средств для лечения тяжелых нервно-мышечных и неврологических заболеваний. Ведущим продуктом компании-кандидата является PGN-EDO51, пептид EDO, проходящий фазу I клинических испытаний для лечения пациентов с мышечной дистрофией Дюшенна (МДД). Он также разрабатывает PGN-EDODM1, конъюгированный с пептидом EDO PMO для лечения миотонической дистрофии 1 типа, а также терапевтические кандидаты EDO, такие как PGN-EDO53, PGN-EDO45 и PGN-EDO44 для лечения МДД.

More details
Компания была основана в 2018 году и имеет штаб-квартиру в Кембридже, штат Массачусетс.


Цена ао 8.33
Сайт https://www.pepgen.com
EV/EBITDA 2.8
EBITDA -0.0012
P/BV 1.92
ISIN US7133171055
Число акций ао 0.0238 млрд
Валюта usd
IPO date 2022-05-06
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: 0% (8.81)
Change price per week: -5.88% (9.36)
Change price per month: -7.07% (9.48)
Change price per 3 month: -51.06% (18)
Change price per half year: -23.39% (11.5)
Change price per year: +62.55% (5.42)
Change price per year to date: +89.06% (4.66)

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.55 8
P/E 0 0
EV/EBITDA -1.29 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -54.96 0
ROE, % -72.52 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2405 10
Total: 7.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 6865.17 10
Yield EPS, % 5397.78 10
Total: 8

Institutions Volume Share, %
RA Capital Management, L.P. 8131952 25.13
Viking Global Investors, L.P. 1482434 4.58
Adage Capital Partners GP L.L.C. 1100000 3.4
Janus Henderson Group PLC 988204 3.05
FMR, LLC 738022 2.28
Blackrock Inc. 723538 2.24
Laurion Capital Management, LP 664516 2.05
Vanguard Group Inc 506179 1.56
Suvretta Capital Management, LLC 486611 1.5
Samsara BioCapital, LLC 436813 1.35

ETF Share, % Profitability for 1 year, % Dividends, %
Avantis U.S Small Cap Equity ETF 0.01592 27.774101036841 1.68271
Avantis U.S. Equity ETF 0.00018 30.365392144069 1.59151
Dimensional U.S. Core Equity 2 ETF 0.00004 30.755198832543 1.47098
Dimensional U.S. Targeted Value ETF 0.00017 26.007247921552 1.93487
Dimensional US Core Equity Market ETF 0.00037 30.983243755928 1.40618
Dimensional U.S. Equity ETF 0.00013 31.530984204131 1.3557
Invesco Dorsey Wright SmallCap Momentum ETF 0.20834 33.912466843501 0.61241
ProShares Hedge Replication ETF 0.00088 5.9237999659878 1.47892
iShares Neuroscience and Healthcare ETF 0.44149 19.720292847757 0.03
iShares Micro-Cap ETF 0.03667 34.327031588619 1.54048
iShares Russell 2000 Growth ETF 0.0092 38.042556988 0.6026
iShares Russell 3000 ETF 0.00046 31.230028873917 1.43482
ProShares UltraPro Russell2000 0.00309 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.01 37.361289927043 0.60264
Vanguard Russell 2000 ETF 0.01 32.773459189339 1.48801



Head Job title Payment Year of birth
Dr. James G. McArthur Ph.D. President, CEO, Treasurer, Secretary & Director 834.98k 1962 (62 years)
Dr. Michelle L. Mellion M.D. Chief Medical Officer N/A 1976 (48 years)
Mr. Niels Svenstrup Ph.D. Senior Vice President of Chemistry, Manufacturing & Control 455.15k 1970 (54 years)
Mr. Noel P. Donnelly M.B.A. Chief Financial Officer 650.17k 1970 (54 years)
Dr. Michael Gait Ph.D. Founder & Scientific Advisory Board Member N/A
Ms. Emiko Bryant Chief of Staff N/A
Mr. David E. Borah C.F.A. Senior VP of IR & Corporate Communications
Ms. Mary Beth DeLena J.D. General Counsel & Secretary 1968 (56 years)
Dr. Hayley Parker Ph.D. Senior Vice President of Global Regulatory Affairs
Dr. Afsaneh Mohebbi Ph.D. Senior VP of Portfolio and Program Management

Address: United States, Cambridge. MA, 245 Main Street - open in Google maps, open in Yandex maps
Website: https://www.pepgen.com